

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 March 2022 (03.03.2022)



(10) International Publication Number
WO 2022/047046 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) C07K 16/46 (2006.01)
C07K 16/00 (2006.01)

(21) International Application Number:

PCT/US2021/047773

(22) International Filing Date:

26 August 2021 (26.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/070,793 26 August 2020 (26.08.2020) US

(71) Applicant: **MARENGO THERAPEUTICS, INC.**
[US/US]; 840 Memorial Drive, 4th Floor, Cambridge, MA
02139 (US).

(72) Inventors: **LOEW, Andreas**; C/o Marengo Therapeutics,
Inc., 840 Memorial Drive, 4th Floor, Cambridge, MA 02139
(US). **KATRAGADDA, Madan**; C/o Marengo Therapeu-
tics, Inc., 840 Memorial Drive, 4th Floor, Cambridge, MA
02139 (US). **GUNTAS, Gurkan**; C/o Marengo Therapeu-
tics, Inc., 840 Memorial Drive, 4th Floor, Cambridge, MA
02139 (US). **MAREK, Peter**; C/o Marengo Therapeutics,
Inc., 840 Memorial Drive, 4th Floor, Cambridge, MA 02139
(US). **PALAKURTHI, Sangeetha**; C/o Marengo Thera-

peutics, Inc., 840 Memorial Drive, 4th Floor, Cambridge,
MA 02139 (US).

(74) Agent: **UM, Moonkyoung**; Wilson Sonsini Goodrich &
Rosati, 650 Page Mill Road, Palo Alto, CA 94304 (US).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS OF DETECTING TRBC1 OR TRBC2

FIG. 1B

Anti-TRBC1



(57) Abstract: Antibody molecules that bind to TRBC1 or TRBC2
are disclosed. Additionally disclosed are methods of detecting TR-
BC1 or TRBC2, methods of evaluating a subject or a disorder, and
kits using the aforesaid antibody molecules.

WO 2022/047046 A1

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*